Page 105 - 南京医科大学学报自然科学版
P. 105

第42卷第4期            孙 伟,于 跃,李 俊,等. 可切除的肺浸润性黏液腺癌的临床特点和预后分析[J].
                  2022年4月                     南京医科大学学报(自然科学版),2022,42(4):549-555                        ·555 ·


                    cinoma:prognostic subgroups and implications for further  [18] SHIMIZU K,OKITA R,SAISHO S,et al. Clinicopatholog⁃
                    revision of staging based on analysis of 514 stage I cases  ical and immunohistochemical features of lung invasive
                    [J]. Mod Pathol,2011,24(5):653-664                 mucinous adenocarcinoma based on computed tomogra⁃
               [8] CADRANEL J,QUOIX E,BAUDRIN L,et al. IFCT⁃0401       phy findings[J]. Oncotargets Ther,2017,10:153-163
                    trial:a phase II study of gefitinib administered as first ⁃  [19] CHA Y J,KIM H R,LEE H J,et al. Clinical course of
                    line treatment in advanced adenocarcinoma with bronchio⁃  stage IV invasive mucinous adenocarcinoma of the lung
                    loalveolar carcinoma subtype[J]. J Thorac Oncol,2009,4  [J]. Lung Cancer Amsterdam Neth,2016,102:82-88
                    (9):1126-1135                                [20] 留永健,李      霁,王世波,等. 晚期肺炎型肺癌:一项中
               [9] MANSUET⁃LUPO A,BOBBIO A,BLONS H,et al. The          国单中心临床⁃放射⁃病理特征回顾性研究及预后分析
                    new histologic classification of lung primary adenocarci⁃  [J]. 中国肺癌杂志,2019,2(6):329-335
                    noma subtypes is a reliable prognostic marker and identi⁃  [21] WANG Y D,LIU J C,HUANG C C,et al. Development
                    fies tumors with different mutation status:the experience  and validation of a nomogram for predicting survival of
                    of a French cohort[J]. Chest,2014,146(3):633-643   pulmonary invasive mucinous adenocarcinoma based on
               [10] LEE H Y,CHA M J,LEE K S,et al. Prognosis in resected  surveillance,epidemiology,and end results(SEER)data⁃
                    invasive mucinous adenocarcinomas of the lung:related  base[J]. BMC Cancer,2021,21(1):148
                    factors and comparison with resected nonmucinous adeno⁃  [22] MATSUI T,SAKAKURA N,KOYAMA S,et al. Compari⁃
                    carcinomas[J]. J Thorac Oncol,2016,11(7):1064-1073  son of surgical outcomes between invasive mucinous and
               [11] WATANABE H,SAITO H,YOKOSE T,et al. Relation        non ⁃ mucinous lung adenocarcinoma[J]. Ann Thorac
                     between thin⁃section computed tomography and clinical  Surg,2021,112(4):1118-1126
                     findings of mucinous adenocarcinoma[J]. Ann Thorac  [23] 严晓娣,史国振,毛旭华. 高通量测序技术检测非小细
                     Surg,2015,99(3):975-981                           胞肺癌相关驱动基因的突变[J]. 南京医科大学学报
               [12] LEE M A,KANG J,LEE H Y,et al. Spread through air  (自然科学版),2021,41(2):193-197
                    spaces(STAS)in invasive mucinous adenocarcinoma of  [24] 曲  杨. 肺伴黏液分泌的腺癌分子表型与临床病理特
                    the lung:Incidence,prognostic impact,and prediction  征和预后相关性研究[D]. 北京:中国人民解放军医学
                    based on clinicoradiologic factors[J]. Thorac Cancer,  院,2016
                    2020,11(11):3145-3154                        [25] GU R M,SHI Z L,DUAN T,et al. Feasibility and safety
               [13]SAITO T,TSUTA K,HONDA O,et al. Prognostic impact    of neoadjuvant alectinib in pulmonary invasive mucinous
                    of mucin spread,tumor cell spread,and invasive size in in⁃  adenocarcinoma with ALK rearrangement:case report
                    vasive mucinous adenocarcinoma of the lung[J]. Lung  and literature review[J]. Oncotargets Ther,2021,14:
                    Cancer Amsterdam Neth,2020,146:50-57               5107-5113
               [14] GOW C H,HSIEH M S,LIU Y N,et al. Clinicopathologi⁃  [26] KADOTA K,YEH Y C,D′ANGELO S P,et al. Associa⁃
                    cal features and survival outcomes of primary pulmonary  tions between mutations and histologic patterns of mucin
                    invasive mucinous adenocarcinoma[J]. Cancers,2021,13  in lung adenocarcinoma:invasive mucinous pattern and
                    (16):4103                                          extracellular mucin are associated with KRAS mutation
               [15]OKI T,AOKAGE K,NOMURA S,et al. Optimal method      [J]. Am J Surg Pathol,2014,38(8):1118-1127
                    for measuring invasive size that predicts survival in inva⁃  [27] HONG D S,FAKIH M G,STRICKLER J H,et al.
                    sive mucinous adenocarcinoma of the lung[J]. J Cancer  KRASG12C inhibition with sotorasib in advanced solid
                    Res Clin Oncol,2020,146(5):1291-1298               tumors[J]. N Engl J Med,2020,383(13):1207-1217
               [16] BOLAND J M,MALESZEWSKI J J,WAMPFLER J A,et   [28] 温少迪,沈     波. 非小细胞肺癌免疫治疗作用机制及临
                    al. Pulmonary invasive mucinous adenocarcinoma and  床研究现状[J]. 南京医科大学学报(自然科学版),
                    mixed invasive mucinous/nonmucinous adenocarcinoma⁃a  2020,40(11):1739-1746
                    clinicopathological and molecular genetic study with sur⁃  [29] JANG Y J,HYUN D G,CHOI C M,et al. Optimizing pal⁃
                    vival analysis[J]. Hum Pathol,2018,71:8-19         liative chemotherapy for advanced invasive mucinous ade⁃
               [17] LUO J Z,WANG R,HAN B H,et al. Analysis of the clini⁃  nocarcinoma of the lung[J]. BMC Cancer,2021,21(1):
                    copathologic characteristics and prognostic of stage I inva⁃  731
                    sive mucinous adenocarcinoma[J]. J Cancer Res Clin On⁃                  [收稿日期] 2021-11-16
                    col,2016,142(8):1837-1845                                                   (本文编辑:蒋 莉)
   100   101   102   103   104   105   106   107   108   109   110